Back to search

Article

Safety, Immunogenicity and Efficacy of Heterologous Boost with an Aerosolized Ad5-nCoV after Two-Dose Priming with Inactivated COVID-19 Vaccines in Adults: A Multicenter, Open-Label Trial

2023-04-07

Abstract excerpt

Background: The aerosolized Ad5-nCoV is the first licensed mucosal respiratory vaccine against SARS-CoV-2 in the word. The safety and efficacy of the aerosolized Ad5-nCoV in large population has not been reported yet.<br><br>Methods: This is a multicenter, open-label trial, aiming to evaluate the safety and immunogenicity with aerosolized Ad5-nCoV in health adults ≥18 years of age, who had received two priming dos...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d8684e81-fa78-5623-927a-f9b90d99755a
DOI
10.2139/ssrn.4409350
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety, Immunogenicity and Efficacy of Heterologous Boost with an Aerosolized Ad5-nCoV after Two-Dose Priming with Inactivated COVID-19 Vaccines in Adults: A Multicenter, Open-Label TrialDOI 10.2139/ssrn.4409350
Safety and Immunogenicity of Heterologous Boost Immunisation With an Aerosolized Ad5-nCoV After Two-Dose Priming With an Inactivated SARS-CoV-2 Vaccine CoronaVac in Adults: A Randomised, Open-Label, Parallel-Control TrialSemantic proximity
Safety and Immunogenicity of Heterologous and Homologous Boosting with Orally Aerosolized or Intramuscular Ad5-nCoV and Inactivated Vaccines in Children and Adolescents: A Randomized, Open-Label, Parallel Controlled, Single-Center StudySemantic proximity
Safety and Immunogenicity of Aerosolised Ad5-nCoV or Intramuscular Ad5-nCoV or Inactivated COVID-19 Vaccine Coronavac Given as the Second Booster Following Three Doses of CoronaVac: A Multicentre, Open-Label, Phase 4, Randomized TrialSemantic proximity
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trialSemantic proximity
Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination StratagySemantic proximity
Efficacy of Heterologous Boosting Using Recombinant SARS-CoV-2 Fusion Protein Vaccine: A Randomized, Double-Blind and Placebo-Controlled Phase III TrialSemantic proximity
Immunogenicity and safety of the homogenous booster shot of a recombinant fusion protein vaccine (V-01) against COVID-19 in healthy adult participants primed with a two-dose regimenSemantic proximity
Efficacy and Safety of a Booster Regimen of Ad26.COV2.S Vaccine against Covid-19Semantic proximity
Phase 1 Study of Safety, Reactogenicity, and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate Administered as Inhalation Boost in SARS-CoV-2 Immunized AdultsSemantic proximity
Titers and capacity of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: a single-blinded, randomized clinical trialSemantic proximity
Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised phase III clinical studySemantic proximity
Intranasal administration of a VLP-based vaccine against COVID-19 induces neutralizing antibodies against SARS-CoV-2 and Variants of ConcernsSemantic proximity
Select a neighboring publication to make it the new centre.